Stage I Breast Cancer AJCC v7 Recruiting Phase 3 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0092280 (Stage I Breast Cancer AJCC v7)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02954874Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerTreatment